<DOC>
	<DOCNO>NCT01873703</DOCNO>
	<brief_summary>The purpose randomize , double-blind , placebo-controlled study determine safety efficacy pracinostat compare placebo combine azacitidine , FDA approve treatment Myelodysplastic Syndrome ( MDS ) .</brief_summary>
	<brief_title>Phase 2 Study Pracinostat With Azacitidine Patients With Previously Untreated Myelodysplastic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Voluntary write informed consent Histologically cytologically document diagnosis MDS ( FrenchAmericanBritish [ FAB ] classification subtype ; classify intermediate 2 ( 1.5 2.0 point ) high risk ( ≥2.5 point ) accord International Prognostic Scoring System risk category , &gt; 5 % &lt; 30 % blast , peripheral blast count &lt; 20,000 Bone marrow aspirate smear bone marrow biopsy within 28 day first study treatment There must clinical indication treatment azacitidine . Previously untreated hypomethylating agent ( prior therapy transfusion , hematopoietic growth factor , immunosuppressive therapy allow ) Eastern Cooperative Oncology Group performance status 0 , 1 , 2 Adequate organ function evidence : 1 . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤2.5 x upper limit normal ( ULN ) ( ≤5 x ULN patient hepatic metastasis 2 . Total bilirubin ≤1.5 x ULN total bilirubin 2 , whichever high 3 . Serum creatinine &lt; 2 mg/dL , creatinine clearance ≤1.5 x ULN 4 . QTcF interval ≤470 msec Female male patient ≥18 yearsofage Male patient surgically sterile willing use adequate contraceptive measure abstain heterosexual intercourse entire study treatment period Female patient surgically sterile post menopausal female patient childbearing potential female patient childbearing potential agree use adequate contraceptive measure abstain intercourse study treatment period , breastfeeding , negative serum pregnancy test ≤7 day prior first study treatment . Willingness ability comply trial followup procedure Received follow within specified time frame prior administration study medication : 1 . Any investigational agent within 14 day 5 halflives prior first study treatment , whichever longer 2 . Previous therapy malignancy within 21 day prior first study treatment , include chemotherapy , immunotherapy , biological hormonal therapy ( 6 week nitrosoureas mitomycin C ) 3 . Hydroxyurea within 48 hour prior first study treatment 4 . Hematopoietic growth factor : erythropoietin , granulocyte colony stimulate factor ( GCSF ) , granulocyte macrophage colony stimulate factor ( GMCSF ) , thrombopoietin receptor agonist least 7 day ( 14 day Aranesp ) prior study enrollment 5 . Major surgery within 4 week prior first study treatment Patients recover side effect previous therapy Cardiopulmonary function exclusion : 1 . Current unstable arrhythmia require treatment 2 . History symptomatic congestive heart failure ( New York Heart Association Classes III IV ) 3 . History myocardial infarction within 6 month enrollment 4 . Current unstable angina Concomitant treatment histone deacetylase ( HDAC ) inhibitor drug significant action HDAC inhibitor , valproic acid , permit Clinical evidence central nervous system involvement Patients gastrointestinal ( GI ) tract disease , cause inability take oral medication , malabsorption syndrome , requirement IV alimentation , prior surgical procedure affect absorption , uncontrolled inflammatory GI disease ( e.g. , Crohn 's disease , ulcerative colitis ) . Active infection HIV chronic hepatitis B C Lifethreatening illness unrelated cancer , serious medical psychiatric illness could , investigator 's opinion , potentially interfere participation study Presence malignant disease within last 12 month , exception adequately treat insitu carcinoma , basal squamous cell carcinoma , nonmelanomatous skin cancer Inability ( include psychological , familial , sociological , geographical condition ) comply trial and/or followup procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>MDS</keyword>
	<keyword>High risk myelodysplastic syndrome</keyword>
	<keyword>Intermediate-2 Myelodysplastic syndrome</keyword>
	<keyword>Untreated</keyword>
</DOC>